Study Condition(s): Psoriasis

A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis (IXORA-P)

Study Alias: RHBP

Study Identifier(s): Tool Tip Icon {{ defaultRegistry.registryAnchorText }} NCT02513550 {{ currentLocaleObject.registryAnchorText }}

Withdrawn Active, not recruiting

Study Purpose

The main purpose of this study is to evaluate the efficacy of ixekizumab dosing regimens in participants with plaque psoriasis

Key Participation Requirements Tool Tip Icon

All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria


Male Female


18+ years

Time Commitment

Your participation could last up to 80 weeks and include approximately 18 visits to the study center
  • Participant must have chronic plaque psoriasis for at least 6 months before the start of the study

  • Participant must not have received phototherapy and/or systemic therapyfor at least 4 weeks prior to enrollment

  • Participant must agree to use reliable method of birth control during the study; women must continue using birth control for at least 12 weeks after stopping study treatment

  • Participant must be willing to avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to enrollment and during the study

  • Participant must not be currently taking or have recently used any biologic agent

  • Participant must not have evidence of tuberculosis, major surgery within 8 weeks of baseline or require surgery during the study

  • Female participant must not be pregnant or breastfeeding

Where to Participate

138 locations are currently available of 180 planned
Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location Status
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Closest Location to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Other Location(s) to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}} {{site.getSiteCTALabel() | translate}}

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.